XML 107 R42.htm IDEA: XBRL DOCUMENT v3.22.0.1
Share capital (Tables)
 12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]  
Schedule of Share Capital
Share capital is composed as follows:
Issued and outstanding
Number of shares
December 31,
 20212020
Ordinary shares no par value103,971,263 102,334,276 
Schedule of Fair Value Assumptions Used for All Equity Based Awards Estimated Using Black-Scholes Option Pricing Model
The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants and for market condition awards. The Company also applied the Monte-Carlo simulation model, with the following underlying assumptions:
Year ended December 31,
 202120202019
Stock Option Plans
Expected term (years)
5.50-6.00
5.50-6.00
5.50-6.00
Expected volatility
60%-63%
54%-56%
55%-61%
Risk-free interest rate
0.78%-1.27%
0.30%-0.86%
1.73%-2.40%
Dividend yield0.00 %0.00 %0.00 %
ESPP
Expected term (years)0.500.500.50
Expected volatility
54%-81%
47%-66%
44%-62%
Risk-free interest rate
0.05%-0.09%
0.17%-1.57%
2.10%-2.51%
Dividend yield0.00 %0.00 %0.00 %
Schedule of Stock Options to Purchase Ordinary Shares
A summary of the status of the Company’s options to purchase ordinary shares as of December 31, 2021 and changes during the year ended on that date is presented below:
Year ended December 31, 2021
 
Number of
options
Weighted
average
exercise
price
Aggregate
intrinsic
value
Outstanding at beginning of year9,220,326 $26.21 
Granted466,360 149.96 
Exercised(1,016,369)20.81 
Forfeited and cancelled(120,995)62.77 
Outstanding at end of year8,549,322 $33.09 $394,997 
Exercisable options5,145,149 $19.76 $285,295 
Schedule of RSUs and PSUs A summary of the status of the Company’s RSUs and PSUs as of December 31, 2021 and changes during the year ended on that date is presented below:
 
Year ended December 31, 2021
 Number of
RSUs/PSUs
Weighted
average
grant date
fair value
price
Aggregate
intrinsic
value
Unvested at beginning of year4,466,151 $54.06 
Granted632,275 138.37 
Vested(569,248)52.63 
Forfeited and cancelled(70,071)94.41 
Unvested at end of year (1)4,459,107 $65.56 $334,790 
(1) Includes PSUs that have a mix of service, market and other milestone performance vesting conditions which are vested upon achievements of market and performance conditions which are not probable, as of December 31, 2021, in accordance with ASC 718 as follows:

December 31, 2021
Number of
PSUs		Fair value at grant date per PSUTotal fair value at grant date
2,703,852 $48.16 $130,218 
108,113 69.37 7,500 
17,712 84.68 1,500 
10,532 94.94 1,000 
189,626 $114.26 $21,667 
3,029,835 $161,885 
Schedule of Equity-Based Compensation Expenses Related to Company's Equity-Based Awards
The total equity-based compensation expense related to all of the Company’s equity incentive plans recognized for the years ended December 31, 2021, 2020 and 2019, was comprised as follows:
Year ended December 31,
 202120202019
Cost of revenues$3,471 $2,221 $2,231 
Research, development and clinical studies27,597 18,125 7,570 
Sales and marketing22,673 17,672 11,897 
General and administrative41,159 37,703 30,718 
Total share-based compensation expense$94,900 $75,721 $52,416 
Schedule of Stock Option Outstanding
Options outstanding as of December 31, 2021 are as follows:
Exercise price
Number
of options
outstanding
Weighted
average
remaining
contractual
term
Number
of options
exercisable
Weighted
average
remaining
contractual
term
$ (years) (years)
0.00 - 10.00
1,116,075 4.481,116,075 4.48
10.01 - 20.00
2,668,814 4.941,787,295 4.74
20.01 - 30.00
1,886,852 5.531,461,424 5.35
30.01 - 40.00
331,417 6.56272,217 6.54
40.01 - 60.00
1,200,783 7.29274,740 7.21
60.01 - 100.00
871,555 8.18227,804 8.13
100.01 - 160.00
462,606 9.255,594 8.85
160.01 - 220.00
11,220 9.42— 0.00
 8,549,322 5.975,145,149 5.24